# CURATE.AI Optimized Modulation for Multiple Myeloma

> **NCT03759093** · PHASE2,PHASE3 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **OTHER:** CURATE.AI-Guided dosage modulation
- **DRUG:** Thalidomide
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03759093
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-10
- **Primary completion:** 2025-09-10
- **Final completion:** 2025-09-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759093, "CURATE.AI Optimized Modulation for Multiple Myeloma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03759093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*